Guardant Health, Inc. $GH Shares Sold by Aberdeen Group plc

Aberdeen Group plc decreased its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 33.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 115,701 shares of the company’s stock after selling 57,560 shares during the quarter. Aberdeen Group plc’s holdings in Guardant Health were worth $7,229,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GH. Allworth Financial LP increased its stake in shares of Guardant Health by 358.4% in the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after acquiring an additional 552 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in shares of Guardant Health in the third quarter valued at about $38,000. FNY Investment Advisers LLC purchased a new stake in shares of Guardant Health in the second quarter valued at about $62,000. Smartleaf Asset Management LLC increased its position in Guardant Health by 162.2% during the third quarter. Smartleaf Asset Management LLC now owns 1,096 shares of the company’s stock worth $68,000 after purchasing an additional 678 shares during the last quarter. Finally, SBI Securities Co. Ltd. raised its stake in Guardant Health by 99.4% during the second quarter. SBI Securities Co. Ltd. now owns 1,366 shares of the company’s stock worth $71,000 after purchasing an additional 681 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $103.10 on Friday. The firm has a market capitalization of $12.99 billion, a PE ratio of -31.15 and a beta of 1.63. The firm’s 50-day moving average is $106.69 and its two-hundred day moving average is $85.94. Guardant Health, Inc. has a 1 year low of $34.88 and a 1 year high of $120.74.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. During the same period last year, the firm posted ($0.62) earnings per share. The business’s revenue for the quarter was up 39.4% on a year-over-year basis. Analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Chris Freeman sold 31,452 shares of Guardant Health stock in a transaction on Friday, December 5th. The stock was sold at an average price of $103.07, for a total value of $3,241,757.64. Following the completion of the transaction, the insider directly owned 25,987 shares in the company, valued at approximately $2,678,480.09. This trade represents a 54.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $103.82, for a total value of $9,402,458.30. Following the transaction, the chief executive officer directly owned 2,047,143 shares of the company’s stock, valued at $212,534,386.26. The trade was a 4.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 434,511 shares of company stock worth $45,580,887 over the last three months. 6.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on GH shares. Mizuho set a $135.00 price target on shares of Guardant Health in a research note on Friday, January 9th. TD Cowen upped their price objective on Guardant Health from $130.00 to $135.00 and gave the company a “buy” rating in a report on Friday. Leerink Partners increased their price objective on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday. UBS Group restated a “buy” rating and issued a $175.00 target price on shares of Guardant Health in a research report on Friday, January 30th. Finally, Robert W. Baird assumed coverage on Guardant Health in a research note on Tuesday. They issued an “outperform” rating and a $120.00 price target on the stock. Twenty-one research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and an average price target of $117.43.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.